SEARCH

SEARCH BY CITATION

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
HEP_24272_sm_suppinfo.doc111KSupporting Information
HEP_24272_sm_suppinfoFig1A.eps84KSupporting Information Fig. S1. Comparison of measured HCV RNA (circle) and best-fit prediction by the CE (dashed line) and VE (solid line) models during the first 3 days of treatment with telaprevir dosed at (A) 450 mg every 8 hours, (B) 750 mg every 8 hours, (C) 1250 mg every 12 hours, (D) 750 mg every 8 hours as tablets, and (E) with telaprevir 750 mg every 8 hours plus PEG-IFN. The first dose of telaprevir was given between 15 and 24 hours after the initial dose of PEG-IFN.4 The number above each figure indicates subject number
HEP_24272_sm_suppinfoFig2.eps69KSupporting Information Fig. S2. Comparison of viral kinetics and treatment effectiveness for the constant effectiveness (CE) and varying effectiveness (VE) models. Bottom panel: mean treatment effectiveness versus time according to the CE (dotted) and VE (solid line) models. Upper panel: viral kinetics predicted by the two models using the mean parameters given in Table 1. Although the two models do not differ much in their predictions early on (first 3 days) (in mean), in the long term, their predictions for HCV RNA decay are very different. The time to reach viral eradication (dashed line) differs from 16 to 30 days
HEP_24272_sm_suppinfoFig1B.eps63KSupporting Information Fig. S1. Comparison of measured HCV RNA (circle) and best-fit prediction by the CE (dashed line) and VE (solid line) models during the first 3 days of treatment with telaprevir dosed at (A) 450 mg every 8 hours, (B) 750 mg every 8 hours, (C) 1250 mg every 12 hours, (D) 750 mg every 8 hours as tablets, and (E) with telaprevir 750 mg every 8 hours plus PEG-IFN. The first dose of telaprevir was given between 15 and 24 hours after the initial dose of PEG-IFN.4 The number above each figure indicates subject number
HEP_24272_sm_suppinfoFig1C.eps82KSupporting Information Fig. S1. Comparison of measured HCV RNA (circle) and best-fit prediction by the CE (dashed line) and VE (solid line) models during the first 3 days of treatment with telaprevir dosed at (A) 450 mg every 8 hours, (B) 750 mg every 8 hours, (C) 1250 mg every 12 hours, (D) 750 mg every 8 hours as tablets, and (E) with telaprevir 750 mg every 8 hours plus PEG-IFN. The first dose of telaprevir was given between 15 and 24 hours after the initial dose of PEG-IFN.4 The number above each figure indicates subject number
HEP_24272_sm_suppinfoFig1D.eps82KSupporting Information Fig. S1. Comparison of measured HCV RNA (circle) and best-fit prediction by the CE (dashed line) and VE (solid line) models during the first 3 days of treatment with telaprevir dosed at (A) 450 mg every 8 hours, (B) 750 mg every 8 hours, (C) 1250 mg every 12 hours, (D) 750 mg every 8 hours as tablets, and (E) with telaprevir 750 mg every 8 hours plus PEG-IFN. The first dose of telaprevir was given between 15 and 24 hours after the initial dose of PEG-IFN.4 The number above each figure indicates subject number
HEP_24272_sm_suppinfoFig1E.eps70KSupporting Information Fig. S1. Comparison of measured HCV RNA (circle) and best-fit prediction by the CE (dashed line) and VE (solid line) models during the first 3 days of treatment with telaprevir dosed at (A) 450 mg every 8 hours, (B) 750 mg every 8 hours, (C) 1250 mg every 12 hours, (D) 750 mg every 8 hours as tablets, and (E) with telaprevir 750 mg every 8 hours plus PEG-IFN. The first dose of telaprevir was given between 15 and 24 hours after the initial dose of PEG-IFN.4 The number above each figure indicates subject number

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.